Abstract: A method for treating or inhibiting a neurological disease, disorder or condition, comprises administering dextran sulfate, or a pharmaceutically acceptable salt thereof, to a subject to treat or inhibit the neurological disease, disorder or condition.

Abstract: A method for dissolving scars comprises administering dextran sulfate, or a pharmaceutically acceptable salt thereof, to a subject suffering from fibrosis or a fibrotic disease, disorder or condition to dissolve an established scar in the subject.

Abstract: The invention relates to dextran sulfate, or a pharmaceutically acceptable salt thereof, for use in prevention, inhibition and/or treatment of a flavivirus infection or infectious disease. The dextran sulfate, or the pharmaceutically acceptable salt thereof, has an average molecular weight equal to or below 10000 Da and an average sulfur content of equal to or above 15%.

Abstract: The present invention relates to the use of dextran sulfate, or a pharmaceutically acceptable salt thereof, in treatment or prevention of muscle atrophy in a subject suffering from sarcopenia and in improving muscle function in a subject suffering from a neuromuscular disease and/or damage or sarcopenia.

Abstract: The invention relates to dextran sulfate, or a pharmaceutically acceptable salt thereof, for use in improving liver function in a subject suffering from a non-alcoholic fatty liver disease (NAFLD). The dextran sulfate, or the pharmaceutically acceptable salt thereof, has an average molecular weight equal to or below 10 000 Da and is formulated for intravenous or subcutaneous administration to the subject.

Abstract: The invention relates to dextran sulfate, or a pharmaceutically acceptable salt thereof, for use in treatment of a coronavirus infection or infectious disease and infections caused by other HSPG binding pathogens. The invention also relates to treatment of inflammatory diseases, such as ARDS and SIRS, which may occur in connection with such infections.

Abstract: The invention relates to dextran sulfate, or a pharmaceutically acceptable salt thereof, in treatment of sepsis and hypercytokinemia.

Abstract: A method for dissolving scars comprises administering dextran sulfate, or a pharmaceutically acceptable salt thereof, to a subject suffering from fibrosis or a fibrotic disease, disorder or condition to dissolve an established scar in the subject.

Abstract: Dextran sulfate, or a pharmaceutically acceptable derivative thereof, is used to induce differentiation of glial cells and neurons. The cell differentiation induction of dextran sulfate has positive effects in subjects suffering from neurological diseases, including neurodegenerative diseases, demyelinating diseases, neuro ischemic diseases and neuromuscular diseases.

Abstract: The efficiency of dextran sulfate treatment is determined based on differences between the amount of biomarkers determined in a second biological sample taken from the patient following dextran sulfate administration and in a first biological sample taken from the patient prior to dextran sulfate administration. The biomarkers are selected from 6 groups consisting of PFA4and VAV3 (group 1); TNFSF15, IL-17B, TSLP and CRH(group 2); FGF1 and KITLG (group 3);BDNF, NOG and HBEGF (group 4);AFP,ATP2A3, SLC29A1,SLC40A1 and TTR(group 5);and SLC1A4, SLC7A11, SLC16A7, LDLR and ATP8A1(group 6).

Abstract: The present embodiments generally relate to dextran sulfate, or a pharmaceutically acceptable salt thereof, for use in treating, inhibiting or preventing glaucoma in a subject. Dextran sulfate of the embodiments achieves a reduction and normalization of intraocular pressure, a neuroprotective effect in terms of preserving retinal ganglion cells and retinal nerve fiber layer and dissolves established trabecular meshwork scar elements.

Abstract: The present embodiments generally relate to dextran sulfate, or a pharmaceutically acceptable salt thereof, for use in treating, inhibiting or preventing glaucoma in a subject. Dextran sulfate of the embodiments achieves a reduction and normalization of intraocular pressure, a neuroprotective effect in terms of preserving retinal ganglion cells and retinal nerve fiber layer and dissolves established trabecular meshwork scar elements.

Abstract: Dextran sulfate, or a pharmaceutically acceptable derivative thereof, is used to induce differentiation of glial cells and neurons. The cell differentiation induction of dextran sulfate has positive effects in subjects suffering from neurological diseases, including neurodegenerative diseases, demyelinating diseases, neuro ischemic diseases and neuromuscular diseases.

Abstract: The present embodiments relate to the use of dextran sulfate having an average molecular weight below 10 000 Da for inducing angiogenesis in a subject and for increasing blood flow in a subject suffering from ischemia.

Abstract: Methods of treating, inhibiting and/or preventing instant blood-mediated inflammatory reaction (IBMIR) comprise administering, to a subject, a dextran sulfate characterized by a number average molecular weight (Mn) as measured by nuclear magnetic resonance (NMR) spectroscopy within an interval of 1850 and 3500 Da; an average sulfate number per glucose unit within an interval of 2.5 and 3.0; and an average sulfation of C2 position in the glucose units of said dextran sulfate of at least 90%, or a salt of such a dextran sulfate.

Abstract: The present embodiments relate to the use of dextran sulfate having an average molecular weight below 10 000 Da for inducing angiogenesis in a subject and for increasing blood flow in a subject suffering from ischemia.

Abstract: Methods of treating, inhibiting and/or preventing instant blood-mediated inflammatory reaction (IBMIR) comprise administering, to a subject, a dextran sulfate characterized by a number average molecular weight (Mn) as measured by nuclear magnetic resonance (NMR) spectroscopy within an interval of 1850 and 3500 Da; an average sulfate number per glucose unit within an interval of 2.5 and 3.0; and an average sulfation of C2 position in the glucose units of said dextran sulfate of at least 90%, or a salt of such a dextran sulfate.

Abstract: The present embodiments relate to the use of dextran sulfate having an average molecular weight below 10 000 Da for inducing angiogenesis in a subject and for increasing blood flow in a subject suffering from ischemia.

Abstract: The present embodiments relate to the use of dextran sulfate formulated for systemic administration for treatment, inhibition or prevention of cardiac fibrosis in a subject.

Abstract: A dextran sulfate, or a salt thereof, has a number average molecular weight (Mn) as measured by NMR spectroscopy within an interval of 1850 and 3500 Da. The dextran sulfate, or the salt thereof, also has an average sulfate number per glucose unit within an interval of 2.5 and 3.0. Furthermore, an average sulfation of C2 position in the glucose units of the dextran sulfate, or the salt thereof, is at least 90%. The dextran sulfate has improved biological effects and/or reduced toxicity as compared to similar dextran sulfate molecules available on the market.